Takeda Canada Inc. (Takeda) is pleased to announce that Héma-Québec has added HyQvia®– (normal immunoglobulin [human] 10% and ...

(Takeda) is pleased to announce that Héma-Québec has added HyQvia ® – (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion) as a ...

The Hyqvia market, showing significant growth in ... A good example is immune globulin infusion, used for treating chronic inflammatory demyelinating polyneuropathy CIDP and primary ...

Takeda Canada Inc., the Canadian organization of Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that non-profit ...

"The reimbursement of HyQvia is welcome news as it is important that patients in Quebec continue to have access to innovative treatments." "Reimbursement for HyQvia is a major development for ...

“The reimbursement of HyQvia is welcome news as it is important that patients in Quebec continue to have access to innovative treatments.” “Reimbursement for HyQvia is a major development for ...

HyQvia is approved in Canada as a replacement ... Notably, it is the only subcutaneous immune globulin infusion that offers a once-monthly administration schedule, either every three or four ...

Additionally, with the growing demand for chronic disease treatments and the ageing baby boomer population, the infusion market is set for significant growth. According to the market research ...

It is important to understand the differences between risk-based decision making and other decision making in a pharmaceutical quality system.